Review



blu0588  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress blu0588
    (A) Assessment of synergy in Cal27 cells treated with a combination of metformin and <t>BLU0588</t> (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.
    Blu0588, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blu0588/product/MedChemExpress
    Average 93 stars, based on 2 article reviews
    blu0588 - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Genome-wide CRISPR screening reveals a PKA-driven resistance mechanism to metformin for oral cancer prevention that can be exploited by combination with NSAIDs"

    Article Title: Genome-wide CRISPR screening reveals a PKA-driven resistance mechanism to metformin for oral cancer prevention that can be exploited by combination with NSAIDs

    Journal: Cancer prevention research (Philadelphia, Pa.)

    doi: 10.1158/1940-6207.CAPR-25-0264

    (A) Assessment of synergy in Cal27 cells treated with a combination of metformin and BLU0588 (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.
    Figure Legend Snippet: (A) Assessment of synergy in Cal27 cells treated with a combination of metformin and BLU0588 (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.

    Techniques Used: Inhibition, In Vitro, Western Blot



    Similar Products

    blu0588  (MedChemExpress)
    93
    MedChemExpress blu0588
    (A) Assessment of synergy in Cal27 cells treated with a combination of metformin and <t>BLU0588</t> (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.
    Blu0588, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blu0588/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    blu0588 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    pka inhibitor blu0588  (TargetMol)
    94
    TargetMol pka inhibitor blu0588
    (A) Assessment of synergy in Cal27 cells treated with a combination of metformin and <t>BLU0588</t> (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.
    Pka Inhibitor Blu0588, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pka inhibitor blu0588/product/TargetMol
    Average 94 stars, based on 1 article reviews
    pka inhibitor blu0588 - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    blu0588  (Blueprint Medicines)
    90
    Blueprint Medicines blu0588
    (A) Assessment of synergy in Cal27 cells treated with a combination of metformin and <t>BLU0588</t> (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.
    Blu0588, supplied by Blueprint Medicines, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blu0588/product/Blueprint Medicines
    Average 90 stars, based on 1 article reviews
    blu0588 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    kinase inhibitors blu0588  (MedChemExpress)
    93
    MedChemExpress kinase inhibitors blu0588
    (A) Assessment of synergy in Cal27 cells treated with a combination of metformin and <t>BLU0588</t> (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.
    Kinase Inhibitors Blu0588, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kinase inhibitors blu0588/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    kinase inhibitors blu0588 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Assessment of synergy in Cal27 cells treated with a combination of metformin and BLU0588 (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.

    Journal: Cancer prevention research (Philadelphia, Pa.)

    Article Title: Genome-wide CRISPR screening reveals a PKA-driven resistance mechanism to metformin for oral cancer prevention that can be exploited by combination with NSAIDs

    doi: 10.1158/1940-6207.CAPR-25-0264

    Figure Lengend Snippet: (A) Assessment of synergy in Cal27 cells treated with a combination of metformin and BLU0588 (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.

    Article Snippet: BLU0588 (cat. #HY-153967) was purchased from MedChemExpress.

    Techniques: Inhibition, In Vitro, Western Blot